Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Upstream BioUPB -3.04%10 Net Margin % is -3,925.63% as of Mar. 2026. GuruFocus rates UPB with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 941 Biotechnology companies, Upstream Bio ranks worse than 89.05% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Upstream Bio's Net Income for the
three
months ended in Mar. 2026 was $-40.59 Mil. Upstream Bio's Revenue for the
three
months ended in Mar. 2026 was $1.03 Mil. Therefore, Upstream Bio's net margin for the quarter that ended in Mar. 2026 was -3,925.63%.
The historical rank and industry rank for Upstream Bio's Net Margin % or its related term are showing as below:
UPB'
s Net Margin % Range Over the Past 10 Years
Min: -5026.03 Med: -2309.68 Max: -862.9
Current: -4718.96
UPB's Net Margin % is ranked worse than 89.05% of 941
companies
in the Biotechnology industry
Industry Median: -88.29
vs UPB: -4718.96
Upstream Bio (NAS:UPB) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Upstream Bio Net Margin % Related Terms
Upstream Bio Net Margin % Historical Data
* Premium members only.
The historical data trend for Upstream Bio's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Upstream Bio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Upstream Bio Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Upstream Bio's Net Margin % distribution charts can be found below:
* The bar in red indicates where Upstream Bio's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Upstream Bio (UPB) has a Net Margin % of -3,925.63% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Upstream Bio and its competitors. According to the industry distribution chart, Upstream Bio ranks #838 out of 941 companies in the Biotechnology industry, placing it in the top 89.1%.
Is Upstream Bio's Net Margin % too high?
Upstream Bio's current Net Margin % is -3,925.63%. Based on the distribution chart, Upstream Bio ranks #838 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Upstream Bio has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Upstream Bio's Net Margin % compare to OABI and VNDA?
According to the Biotechnology industry distribution chart, Upstream Bio ranks #838 out of 941 companies for Net Margin %. This places Upstream Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Upstream Bio and its competitors. Upstream Bio's current Net Margin % is -3,925.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Upstream Bio stock overvalued right now?
Upstream Bio (UPB) has a current Net Margin % of -3,925.63%. The current Net Margin % is -3,925.63%. Upstream Bio's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Upstream Bio (UPB), the current Net Margin % is -3,925.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
10GF Score
Get the complete analysis for UPB
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPB has been successfully added to your 
